Selective use of splenectomy after liver transplantation in children

Stephen M. Megison, Neil D. McMullin, Walter S. Andrews

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In a series of 106 pediatric liver transplantations, five patients were identified with recurrent rejection who could not tolerate the addition of azathioprine (Aza) to their immunosuppressive therapy because of leukopenia. Splenectomy was performed posttransplantation to allow the use of Aza. The number and severity of rejection episodes were compared before and after splenectomy in these patients. In addition, presplenectomy and postsplenectomy rejection frequencies were compared with rejection frequencies in 35 patients who did not require splenectomy and had at least 1 1 2 years of follow-up. Mild, moderate, and severe rejection episodes were defined by the treatment (mild, steroid bolus only; moderate, steroid recycle; and severe, monoclonal antibodies or Minnesota antilymphocyte globulin) required to produce complete resolution. There was a mean of 342 ± 111 days from transplantation to splenectomy and a mean of 674 ± 109 days of follow-up after splenectomy. Follow-up in the control group was 934 ± 44 days. After splenectomy, the average platelet count increased from 78 ± 15 to 514 ± 113 (P = .020) and white blood cell count increased from 3.2 ± 0.6 to 16.7 ± 2.7 (P = .010). Splenectomy permitted the implementation of Aza therapy in one patient who previously was not a candidate because of hypersplenism and allowed uncomplicated Aza therapy in four patients who became severely leukopenic during previous Aza trials. All five patients who underwent splenectomy demonstrated a statistically significant (P < .05) decrease in the total number of rejection episodes. Rejection frequency after splenectomy was no different from the rejection frequency in patients who did not require splenectomy (P = .682). These data suggest that patients who have recurrent graft rejection and are not candidates for Aza therapy, the combination of splenectomy and Aza can decrease the frequency of rejection episodes.

Original languageEnglish (US)
Pages (from-to)881-884
Number of pages4
JournalJournal of Pediatric Surgery
Volume25
Issue number8
DOIs
StatePublished - 1990

Fingerprint

Splenectomy
Liver Transplantation
Azathioprine
Steroids
Hypersplenism
Therapeutics
Antilymphocyte Serum
Leukopenia
Graft Rejection
Immunosuppressive Agents
Platelet Count
Leukocyte Count
Transplantation
Monoclonal Antibodies
Pediatrics
Control Groups

Keywords

  • azathioprine
  • Liver transplantation
  • splenectomy

ASJC Scopus subject areas

  • Surgery

Cite this

Selective use of splenectomy after liver transplantation in children. / Megison, Stephen M.; McMullin, Neil D.; Andrews, Walter S.

In: Journal of Pediatric Surgery, Vol. 25, No. 8, 1990, p. 881-884.

Research output: Contribution to journalArticle

Megison, Stephen M. ; McMullin, Neil D. ; Andrews, Walter S. / Selective use of splenectomy after liver transplantation in children. In: Journal of Pediatric Surgery. 1990 ; Vol. 25, No. 8. pp. 881-884.
@article{1e30a4bedf9140419af3b083be162ccc,
title = "Selective use of splenectomy after liver transplantation in children",
abstract = "In a series of 106 pediatric liver transplantations, five patients were identified with recurrent rejection who could not tolerate the addition of azathioprine (Aza) to their immunosuppressive therapy because of leukopenia. Splenectomy was performed posttransplantation to allow the use of Aza. The number and severity of rejection episodes were compared before and after splenectomy in these patients. In addition, presplenectomy and postsplenectomy rejection frequencies were compared with rejection frequencies in 35 patients who did not require splenectomy and had at least 1 1 2 years of follow-up. Mild, moderate, and severe rejection episodes were defined by the treatment (mild, steroid bolus only; moderate, steroid recycle; and severe, monoclonal antibodies or Minnesota antilymphocyte globulin) required to produce complete resolution. There was a mean of 342 ± 111 days from transplantation to splenectomy and a mean of 674 ± 109 days of follow-up after splenectomy. Follow-up in the control group was 934 ± 44 days. After splenectomy, the average platelet count increased from 78 ± 15 to 514 ± 113 (P = .020) and white blood cell count increased from 3.2 ± 0.6 to 16.7 ± 2.7 (P = .010). Splenectomy permitted the implementation of Aza therapy in one patient who previously was not a candidate because of hypersplenism and allowed uncomplicated Aza therapy in four patients who became severely leukopenic during previous Aza trials. All five patients who underwent splenectomy demonstrated a statistically significant (P < .05) decrease in the total number of rejection episodes. Rejection frequency after splenectomy was no different from the rejection frequency in patients who did not require splenectomy (P = .682). These data suggest that patients who have recurrent graft rejection and are not candidates for Aza therapy, the combination of splenectomy and Aza can decrease the frequency of rejection episodes.",
keywords = "azathioprine, Liver transplantation, splenectomy",
author = "Megison, {Stephen M.} and McMullin, {Neil D.} and Andrews, {Walter S.}",
year = "1990",
doi = "10.1016/0022-3468(90)90196-G",
language = "English (US)",
volume = "25",
pages = "881--884",
journal = "Journal of Pediatric Surgery",
issn = "0022-3468",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - Selective use of splenectomy after liver transplantation in children

AU - Megison, Stephen M.

AU - McMullin, Neil D.

AU - Andrews, Walter S.

PY - 1990

Y1 - 1990

N2 - In a series of 106 pediatric liver transplantations, five patients were identified with recurrent rejection who could not tolerate the addition of azathioprine (Aza) to their immunosuppressive therapy because of leukopenia. Splenectomy was performed posttransplantation to allow the use of Aza. The number and severity of rejection episodes were compared before and after splenectomy in these patients. In addition, presplenectomy and postsplenectomy rejection frequencies were compared with rejection frequencies in 35 patients who did not require splenectomy and had at least 1 1 2 years of follow-up. Mild, moderate, and severe rejection episodes were defined by the treatment (mild, steroid bolus only; moderate, steroid recycle; and severe, monoclonal antibodies or Minnesota antilymphocyte globulin) required to produce complete resolution. There was a mean of 342 ± 111 days from transplantation to splenectomy and a mean of 674 ± 109 days of follow-up after splenectomy. Follow-up in the control group was 934 ± 44 days. After splenectomy, the average platelet count increased from 78 ± 15 to 514 ± 113 (P = .020) and white blood cell count increased from 3.2 ± 0.6 to 16.7 ± 2.7 (P = .010). Splenectomy permitted the implementation of Aza therapy in one patient who previously was not a candidate because of hypersplenism and allowed uncomplicated Aza therapy in four patients who became severely leukopenic during previous Aza trials. All five patients who underwent splenectomy demonstrated a statistically significant (P < .05) decrease in the total number of rejection episodes. Rejection frequency after splenectomy was no different from the rejection frequency in patients who did not require splenectomy (P = .682). These data suggest that patients who have recurrent graft rejection and are not candidates for Aza therapy, the combination of splenectomy and Aza can decrease the frequency of rejection episodes.

AB - In a series of 106 pediatric liver transplantations, five patients were identified with recurrent rejection who could not tolerate the addition of azathioprine (Aza) to their immunosuppressive therapy because of leukopenia. Splenectomy was performed posttransplantation to allow the use of Aza. The number and severity of rejection episodes were compared before and after splenectomy in these patients. In addition, presplenectomy and postsplenectomy rejection frequencies were compared with rejection frequencies in 35 patients who did not require splenectomy and had at least 1 1 2 years of follow-up. Mild, moderate, and severe rejection episodes were defined by the treatment (mild, steroid bolus only; moderate, steroid recycle; and severe, monoclonal antibodies or Minnesota antilymphocyte globulin) required to produce complete resolution. There was a mean of 342 ± 111 days from transplantation to splenectomy and a mean of 674 ± 109 days of follow-up after splenectomy. Follow-up in the control group was 934 ± 44 days. After splenectomy, the average platelet count increased from 78 ± 15 to 514 ± 113 (P = .020) and white blood cell count increased from 3.2 ± 0.6 to 16.7 ± 2.7 (P = .010). Splenectomy permitted the implementation of Aza therapy in one patient who previously was not a candidate because of hypersplenism and allowed uncomplicated Aza therapy in four patients who became severely leukopenic during previous Aza trials. All five patients who underwent splenectomy demonstrated a statistically significant (P < .05) decrease in the total number of rejection episodes. Rejection frequency after splenectomy was no different from the rejection frequency in patients who did not require splenectomy (P = .682). These data suggest that patients who have recurrent graft rejection and are not candidates for Aza therapy, the combination of splenectomy and Aza can decrease the frequency of rejection episodes.

KW - azathioprine

KW - Liver transplantation

KW - splenectomy

UR - http://www.scopus.com/inward/record.url?scp=0025079680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025079680&partnerID=8YFLogxK

U2 - 10.1016/0022-3468(90)90196-G

DO - 10.1016/0022-3468(90)90196-G

M3 - Article

C2 - 2401944

AN - SCOPUS:0025079680

VL - 25

SP - 881

EP - 884

JO - Journal of Pediatric Surgery

JF - Journal of Pediatric Surgery

SN - 0022-3468

IS - 8

ER -